Market cap
$11.1bn
Earnings yield vs 10-yr compares what the business earns per pound invested against the 5.28% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.
Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.
The increase in Net Product Revenues for the three and six months ended June 30, 2026 as compared to the three and six months ended June 30, 2025 was primarily attributed to the following: • GALAFOLD and POMBILITI + OPFOLDA: revenues from commercial products acquired on April 27, 2026; • VOXZOGO: higher sales volume from new patients initiating therapy across all regions; and • PALYNZIQ: higher sales volume from new patients initiating therapy, primarily in the U.S. These increases were partially offset by the following: Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued) (In millions of U.S. …BIOMARIN PHARMACEUTICAL INC, 10-Q, period ended 2026-06-30, filed 2026-08-06